- Trials with a EudraCT protocol (19)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
19 result(s) found for: Replication protein A.
Displaying page 1 of 1.
EudraCT Number: 2010-024496-37 | Sponsor Protocol Number: 1716-12 | Start Date*: 2012-05-04 | |||||||||||
Sponsor Name:Virttu Biologics Limited | |||||||||||||
Full Title: A PHASE I/IIa STUDY OF THE SAFETY, TOLERABILITY AND BIOLOGICAL EFFECT OF SINGLE AND REPEAT ADMINISTRATION OF THE SELECTIVELY REPLICATION-COMPETENT HERPES SIMPLEX VIRUS HSV1716 INTO THE TUMOUR-BEAR... | |||||||||||||
Medical condition: Malignant Pleural Mesothelioma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-004714-28 | Sponsor Protocol Number: 202090 | Start Date*: 2015-09-21 |
Sponsor Name:GlaxoSmithKline Biologicals | ||
Full Title: A Phase 2, randomised, observer-blind, controlled, multi country study to assess the safety and immunogenicity of a single intramuscular dose of GSK Biologicals’ investigational recombinant chimpan... | ||
Medical condition: Primary immunisation against Ebola Zaire virus on healthy volunteers | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2023-000283-62 | Sponsor Protocol Number: KB103-001 | Start Date*: 2023-03-21 | |||||||||||
Sponsor Name:Krystal Biotech | |||||||||||||
Full Title: A Phase I/II Study of KB103, a Non-Integrating, Replication-Incompetent HSV Vector Expressing the Human Collagen VII Protein, for the Treatment of Dystrophic Epidermolysis Bullosa (DEB) | |||||||||||||
Medical condition: Dystrophic Epidermolysis Bullosa | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-018295-24 | Sponsor Protocol Number: AI444-010 | Start Date*: 2010-07-12 | |||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | |||||||||||||
Full Title: A Phase 2b Study of BMS-790052 in Combination with Peg-Interferon Alfa-2a and Ribavirin in Treatment Naive Subjects with Chronic Hepatitis C Genotype 1 and 4 Infection Revised Protocol Number ... | |||||||||||||
Medical condition: Chronic Hepatitis C | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) DE (Completed) FR (Completed) IT (Completed) DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-003102-26 | Sponsor Protocol Number: HIV-CORE007 | Start Date*: 2021-07-14 | |||||||||||
Sponsor Name:OSPEDALE SAN RAFFAELE | |||||||||||||
Full Title: Therapeutic vaccination: A Phase I/II Randomized, Placebo-Controlled Trial of ChAdOx1.tHIVconsvX prime-MVA.tHIVconsvX Boost Vaccination Regimen in Early-treated durably-controlling HIV-1 positive A... | |||||||||||||
Medical condition: HIV infection | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-000274-20 | Sponsor Protocol Number: GNT-WAS-03 | Start Date*: 2014-05-14 | |||||||||||
Sponsor Name:Genethon | |||||||||||||
Full Title: LONG TERM SAFETY FOLLOW UP OF PATIENTS ENROLLED IN THE PHASE I/II CLINICAL TRIAL OF HAEMATOPOIETIC STEM CELL GENE THERAPY FOR THE WISKOTT-ALDRICH SYNDROME(GTG 002-07 AND GTG 003-08) | |||||||||||||
Medical condition: Wiskott-Aldrich syndrome (WAS) is a rare X-linked immunodeficiency caused by mutations in a single gene ,the Wiskott-Aldrich Syndrome Protein (WASP). WAS is characterised by micro-thrombocytopeni... | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) FR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-000972-40 | Sponsor Protocol Number: IM101-774 | Start Date*: 2020-06-09 | |||||||||||
Sponsor Name:Universitätsklinikum Freiburg | |||||||||||||
Full Title: Safety and Efficacy of abatacept (s.c.) in patients with CTLA4 insufficiency or LRBA deficiency | |||||||||||||
Medical condition: Patients with a molecular confirmed diagnosis of CTLA4 (cytotoxic T-lymphocyte-associated Protein 4) (haplo)-insufficiency or LRBA (Lipopolysaccharide-Responsive and Beige-like An¬chor) deficiency | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-019378-34 | Sponsor Protocol Number: AI444-011 | Start Date*: 2010-09-06 | |||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | |||||||||||||
Full Title: A Phase 2B Study of BMS-790052 in Combination with Peginterferon Alfa-2a and Ribavirin in Chronic Hepatitis C Genotype 1 Infected Subjects Who are Null or Partial Responders to Prior Treatment with... | |||||||||||||
Medical condition: Chronic Hepatitis C | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) SE (Completed) IT (Completed) DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-001379-18 | Sponsor Protocol Number: QEL-001-CLN-01 | Start Date*: 2023-07-07 | |||||||||||
Sponsor Name:Quell Therapeutics Limited | |||||||||||||
Full Title: A single-arm, open-label, multi-centre, phase I/II study evaluating the safety and clinical activity of QEL-001, an autologous CAR T regulatory cell treatment targeting HLA-A2, in HLA-A2/ A28neg pa... | |||||||||||||
Medical condition: Prevention of liver transplant rejection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Trial now transitioned) ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-003176-16 | Sponsor Protocol Number: ADP-0055-003/GOG-3084 | Start Date*: 2023-07-03 |
Sponsor Name:Adaptimmune LLC | ||
Full Title: A PHASE 2, OPEN-LABEL, RANDOMIZED, NON-COMPARATIVE CLINICAL TRIAL OF ADP-A2M4CD8 MONOTHERAPY AND IN COMBINATION WITH NIVOLUMAB IN SUBJECTS WITH RECURRENT OVARIAN CANCERS (SURPASS-3 STUDY/ GOG-3084) | ||
Medical condition: Recurrent ovarian cancer positive for MAGE-A4 in human leukocyte antigen (HLA)-A2+ subjects | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: FR (Trial now transitioned) ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2012-001141-41 | Sponsor Protocol Number: 08-C-0007 | Start Date*: 2012-09-18 | |||||||||||
Sponsor Name:National Cancer Institute NCI | |||||||||||||
Full Title: A PHASE I STUDY OF IPILIMUMAB (ANTI-CTLA-4) IN CHILDREN, ADOLESCENTS, AND YOUNG ADULTS WITH TREATMENT REFRACTORY CANCER | |||||||||||||
Medical condition: Sarcoma - Wilm's Tumor - Lymphoma - Neuroblastoma | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-004308-11 | Sponsor Protocol Number: GTG002.07 | Start Date*: 2010-01-11 | |||||||||||
Sponsor Name:Genethon | |||||||||||||
Full Title: PHASE I/II CLINICAL TRIAL OF HAEMATOPOIETIC STEM CELL GENE THERAPY FOR THE WISKOTT-ALDRICH SYNDROME | |||||||||||||
Medical condition: Wiskott-Aldrich syndrome (WAS) is a rare X-linked immunodeficiency caused by mutations in a single gene ,the Wiskott-Aldrich Syndrome Protein (WASP). WAS is characterised by micro-thrombocytopenia,... | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-003842-18 | Sponsor Protocol Number: OTL-103-4 | Start Date*: 2019-01-08 | |||||||||||
Sponsor Name:Orchard Therapeutics Ltd. | |||||||||||||
Full Title: A Single Arm, Open Label Clinical Study of Haematopoietic Stem Cell Gene Therapy with Cryopreserved Autologous CD34+ Cells Transduced with Lentiviral Vector encoding WAS cDNA in Subjects with Wisko... | |||||||||||||
Medical condition: Wiskott-Aldrich Syndrome | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male | ||||||||||||
Trial protocol: IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-022568-11 | Sponsor Protocol Number: AI452-008 | Start Date*: 2011-04-20 | |||||||||||
Sponsor Name:Bristol Myers Squibb International Corporation | |||||||||||||
Full Title: A Phase 2B, randomized study to evaluate the safety and efficacy of Pegylated Interferon Lambda (BMS-914143) administered with Ribavirin plus a single direct antiviral agent (BMS-790052 or BMS-6500... | |||||||||||||
Medical condition: Chronic Hepatitis C | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) IT (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-004124-10 | Sponsor Protocol Number: 68284528MMY2003 | Start Date*: 2020-08-07 | |||||||||||
Sponsor Name:Janssen-Cilag International NV | |||||||||||||
Full Title: A Phase 2, Multicohort Open-Label Study of JNJ-68284528, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA in Subjects with Multiple Myeloma | |||||||||||||
Medical condition: Multiple Myeloma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) DE (Trial now transitioned) BE (Trial now transitioned) ES (Ongoing) NL (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-000589-39 | Sponsor Protocol Number: ADP-0044-002 | Start Date*: 2020-02-13 | |||||||||||||||||||||
Sponsor Name:Adaptimmune LLC | |||||||||||||||||||||||
Full Title: A Phase 2 Single Arm Open-Label Clinical Trial of ADP-A2M4 SPEAR™ T cells in subjects with Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma | |||||||||||||||||||||||
Medical condition: Advanced Synovial Sarcoma Myxoid/Round Cell Liposarcoma | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: FR (Trial now transitioned) GB (GB - no longer in EU/EEA) ES (Ongoing) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-002054-37 | Sponsor Protocol Number: 1000053649 | Start Date*: 2019-09-18 | |||||||||||||||||||||
Sponsor Name:Hospital for Sick Children | |||||||||||||||||||||||
Full Title: Pilot Study of Nivolumab in Pediatric Patients with Hypermutant Cancers | |||||||||||||||||||||||
Medical condition: HYPERMUTANT CANCERS | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: FR (Ongoing) ES (Prematurely Ended) GB (GB - no longer in EU/EEA) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-005802-24 | Sponsor Protocol Number: ADP-0055-002 | Start Date*: 2022-03-21 | |||||||||||
Sponsor Name:Adaptimmune LLC | |||||||||||||
Full Title: A Phase 2 Open-Label Clinical Trial of ADP-A2M4CD8 in Subjects with Advanced Esophageal or Esophagogastric Junction Cancers | |||||||||||||
Medical condition: advanced esophageal or esophagogastric junction (EGJ) cancers | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) ES (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-004888-31 | Sponsor Protocol Number: 208750 | Start Date*: 2020-01-27 | ||||||||||||||||||||||||||
Sponsor Name:GlaxoSmithKline research & development Ltd. | ||||||||||||||||||||||||||||
Full Title: Long-Term Follow-Up (LTFU) of Participants Treated with GSK Adoptive Cell Therapies | ||||||||||||||||||||||||||||
Medical condition: Synovial sarcoma Multiple myeloma Non-small cell lung cancer Myxoid liposarcoma | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: NL (Trial now transitioned) SE (Completed) IT (Trial now transitioned) FR (Prematurely Ended) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
